Tracer library / [177Lu]Lu-DOTA-ABDB6

[177Lu]Lu-DOTA-ABDB6

Also written as [Lu-177]Lu-DOTA-ABDB6

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: Nanobody-based DOTA conjugate (CD70-targeted nanobody derivative)
Target / mechanism: CD70 PMID 42259600
Clinical application: Multiple myeloma PMID 42259600
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	92.5%	>95%	DOTA-ABDB6 Biointron Biological	42259600 2026 J Immunother Cancer For the [177Lu]Lu-labeling process, a solution of [177Lu]LuCl3 (59.2 MBq) was mixed with 200 µL of 0.25 M NaOAc (pH=5.5). - radiochemical yields of 75.6% and 92.5%, respectively

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Biointron Biological
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-ABDB6, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42259600. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42259600: 'DOTA-ABDB6'.